A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)
Clinical trial NCT00240929 · COMPLETED
Trial details
- NCT number
- NCT00240929
- Sponsor
- MedImmune LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2002-09-01
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.